|
Online CME Activity
76-Year-Old Woman With Short-Term Memory Difficulties
|
76-Year-Old Woman With Short-Term Memory Difficulties
2.00 AMA PRA Category 1 Credits™, 2.00 AANP, 2.00 ANCC
Learning Objective
- Recognize the signs and symptoms of Alzheimer’s disease.
- Outline the steps important in arriving at an accurate and clear diagnosis of dementia, and educate patients and their families on the process.
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 2.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 2.00 |
AANP |
Pri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 2 contact hours of continuing education, which includes 1 hours of pharmacology. |
| 2.00 |
ANCC |
Pri-Med Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
This activity for 2 contact hours is provided by Pri-Med Institute. |
Faculty and Editorial Board
Written By:
Sid Gilman, MD, FRCP, William J. Herdman Distinguished University Professor of Neurology, Director, Michigan Alzheimer’s Disease Research Center, University of Michigan, Ann Arbor, Michigan
Reviewed By:
University of Wisconsin School of Medicine and Public Health
Edited By:
Zachary Schwartz, MSc, ELS, Pri-Med Institute
Financial Disclosure Statement(s)
Dr Gilman serves as chair of the Safety Monitoring Committees for Phase III and Phase II trials for Janssen and Wyeth and for Elan and Transition Therapeutics. He serves on the Scientific Advisory Committees for Adamas Pharmaceuticals and for Longitude Capital.
Mr Schwartz has no financial relationships to disclose.
Commercial Support:
Forest Research Institute, Inc. and Eisai Inc.
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|
